Last reviewed · How we verify
Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose — Competitive Intelligence Brief
phase 2
Live · refreshed every 30 min
Target snapshot
Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose (variant-adapted-bnt162b2-omicron-kp-2-10-microgram-dose) — Pfizer Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose TARGET | variant-adapted-bnt162b2-omicron-kp-2-10-microgram-dose | Pfizer Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose CI watch — RSS
- Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose CI watch — Atom
- Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose CI watch — JSON
- Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose alone — RSS
Cite this brief
Drug Landscape (2026). Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose — Competitive Intelligence Brief. https://druglandscape.com/ci/variant-adapted-bnt162b2-omicron-kp-2-10-microgram-dose. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab